In light of the powerful anti-inflammatory effects of antagonization of CD40–CD40L signaling (example provided for type 2 diabetes mellitus and obesity in Figure 3), it would be a waste of resources not to push forward the pharmacological exploitation of this important pathway. The gene discussed is CD40; the disease is obesity due to melanocortin 4 receptor deficiency.